BACKGROUND: Infants with ductal-dependent pulmonary blood flow may undergo palliation with either a patent ductus arteriosus (PDA) stent or a modified Blalock-Taussig (BT) shunt. A balanced multicenter comparison of these 2 approaches is lacking.
I
nfants with various forms of congenital heart disease that include ductal-dependent pulmonary blood flow often require an early palliative procedure to augment or establish a reliable source of pulmonary blood flow until the suitable time when a more definitive reparative or palliative surgical procedure can be performed. Historically, this has been most commonly accomplished with a modified Blalock-Taussig (BT) shunt, although the potential for morbidity and mortality associated with this procedure has been recognized and persists. [1] [2] [3] Patent ductus arteriosus (PDA) stent implantation was introduced in 1992 as an alternative method to provide a stable source of pulmonary blood flow. 4 Since that original description, there have been numerous reports of the safety and feasibility of this approach, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] which has the potential advantages of avoiding cardiothoracic surgery in the neonatal period and stimulating better and more symmetrical pulmonary artery growth. [16] [17] [18] However, there are also potential disadvantages of a PDA stent, including unique procedural complications, concerns about the durability of stent patency, 19 and technical hurdles at subsequent surgical procedures. 20 Direct comparisons of the BT shunt and PDA stent as a palliative procedure for infants with ductal-dependent pulmonary blood flow have been limited to a small number of single-center studies [21] [22] [23] without either the sample size or case mix to make a meaningful comparison of relevant outcomes. In nonrandomized observational studies like these, there is risk for substantial bias resulting from confounding by indication in which a factor (or factors) influences both the particular treatment strategy to which a patient is assigned and the outcome of interest. In an attempt to minimize this potential source of bias, we sought to compare the PDA stent and BT shunt as palliative options for infants with ductal-dependent pulmonary blood flow using a multicenter collaborative that would provide both the sample size and practice variability needed to compare outcomes adjusted for patient-level differences that may affect assignment to a particular treatment strategy.
METHODS
The data, analytical methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
A retrospective cohort study was performed that included all infants with ductal-dependent pulmonary blood flow and confluent pulmonary arteries palliated at <1 year of age with either a BT shunt (from January 1, 2012) or PDA stent (from January 1, 2008) through November 1, 2015 , at the 4 member centers of the Congenital Catheterization Research Collaborative. The differing inclusion dates for each treatment strategy were intentionally chosen to capture the entire PDA stent experience at all 4 centers while maintaining a contemporary cohort of patients receiving a BT shunt at an approximate ratio of 2:1 (BT shunt to PDA stent) to optimize statistical power. Patients were excluded if there was a source of pulmonary blood flow other than the ductus arteriosus or native pulmonary outflow tract (eg, major aortopulmonary collateral vessels), if the branch pulmonary arteries were discontinuous, or if additional surgical or catheter-based interventions were required at the time of initial palliation other than interventions on the pulmonary outflow tract. All available medical records were reviewed, including all follow-up data through December 24, 2015 . The Congenital Catheterization Research Collaborative, previously described, 24 comprises investigators from the Children's Hospital of Philadelphia, Cincinnati Children's Hospital Medical Center, Children's Healthcare of Atlanta, and Texas Children's Hospital. Individual centers performed the detailed medical record review of their own patients. Deidentified data were then collected and managed in a common central database with Research Electronic Data Capture 25 tools hosted at Children's Healthcare of Atlanta, which serves as the data coordinating center for the Congenital Catheterization Research Collaborative. This study was approved by the Institutional Review Board at each participating center with a waiver of the need for informed consent.
Outcomes
The primary outcome was defined a priori as a composite of death or unplanned reintervention to treat cyanosis. An
Clinical Perspective
What Is New?
• Using a multicenter collaborative, we compared surgical Blalock-Taussig shunt and transcatheter patent ductus arteriosus stent as initial palliation for infants with ductal-dependent pulmonary blood flow.
• Although the observed risk of the primary outcome (death or unplanned reintervention to treat cyanosis) was higher in the Blalock-Taussig shunt group, there was no significant difference between groups after adjustment for patient-level factors.
• After adjustment for patient factors, other outcomes favored the patent ductus arteriosus stent group, including fewer procedural complications, shorter intensive care unit length of stay, less frequent need for diuretics, and larger and more symmetrical pulmonary arteries at last follow-up.
What Are the Clinical Implications?
• These findings support patent ductus arteriosus stent placement as a preferable alternative palliative strategy to Blalock-Taussig shunt placement in select patients with ductal-dependent pulmonary blood flow, particularly in experienced centers where this procedure can be performed safely and effectively.
• Further research is needed to determine specific anatomic characteristics of patients who would be most likely to benefit from patent ductus arteriosus stent placement.
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unplanned reintervention to treat cyanosis was defined as an intervention designed to increase oxygen saturation performed during an otherwise unplanned catheterization or surgical procedure that was prompted by clinically concerning cyanosis. Given the variability in what may be considered clinically concerning cyanosis between patients and providers, no objective standard for oxygen saturation was used. Instead, if the medical record made clear that the intervention was performed in an unplanned manner because of concern for cyanosis, then the outcome was established. Cases in which this outcome was less clearly established were reviewed on regular study conference calls to ensure consistency in the manner in which this outcome was classified. An unplanned reintervention to treat cyanosis was combined with death as a composite end point with the notion that such an event could represent a patient at risk for impending sudden cardiovascular death. Secondary outcomes included the individual components of the primary outcome, procedural complications, intensive care unit (ICU) length of stay (LOS), hospital LOS, diuretic use at hospital discharge, other reinterventions (both planned and unplanned to treat concerns other than cyanosis), and branch pulmonary artery size at last follow-up. The at-risk period for developing any of these outcomes began at the time of the initial palliative procedure and ended at the time of subsequent definitive surgical repair. For patients with expected 2-ventricle physiology, the subsequent definitive surgical repair typically consisted of a complete anatomic repair. For patients with expected single-ventricle physiology, the subsequent definitive surgical repair typically consisted of a palliative superior cavopulmonary connection. For patients who did not undergo a definitive surgical repair, the at-risk period extended to the point of last follow-up or study end date. Pulmonary artery size was assessed by all imaging modalities available at a time closest to definitive surgical repair or last follow-up. For patients with pulmonary artery size measurements made by echocardiography, magnetic resonance imaging, or computed tomography, the dimensions of the pulmonary arteries were abstracted from the imaging reports. For patients with angiographic imaging of the pulmonary arteries, the primary images were reread by an expert reviewer at each center (A.C.G., C.J.P., B.H.G., A.M.Q.) with the vessel diameter measured in a systolic frame at the hilum, proximal to the origin of the upper lobe vessels. For patients who had pulmonary artery size assessed by >1 imaging modality, the following prioritization schema was created to select which measurement was used in the analysis: angiography>computed tomography>magnetic resonance imaging>echocardiography. Pulmonary artery size was quantified in 2 ways: the Nakata index, 26 the summed cross-sectional area (assuming a cylindrical vessel) of the right and left pulmonary arteries indexed to the patient's body surface area, and a measure we called the symmetry index, a ratio of diameters of the smaller pulmonary artery to the larger pulmonary artery. The symmetry index is always ≤1, with values closer to 1 reflecting more symmetrical vessel size.
Statistical Analysis
Statistical analyses were performed by the Congenital Catheterization Research Collaborative's data coordinating center using SAS version 9.4 (SAS Institute Inc, Cary, NC), and statistical significance was assessed at the 0.05 level.
Normality of continuous variables was assessed with histogram, normal probability plots, and the Anderson-Darling test for normality. Descriptive statistics are presented as counts and percentages for categorical variables and median (25th-75th percentile) for continuous data with skewed distributions. Continuous data were compared between patients treated with a PDA stent and those treated with a BT shunt with the use of Wilcoxon rank-sum tests, and comparisons between categorical variables were performed with χ 2 tests or Fisher exact test when expected cell counts were <5.
Because groups were not equal at baseline (Table 1) , inverse probability of treatment weighting with propensity scores was used to control for potential confounders and baseline differences between groups. The propensity score was estimated with a logistic regression model in which treatment assignment (PDA stent versus BT shunt, with BT shunt as the reference) was regressed on 6 variables thought to be associated with treatment assignment: center, expected ultimate physiology, presence of antegrade pulmonary blood flow, underlying anatomic diagnosis, preintervention inotrope use, and preintervention mechanical ventilation (the model formulation for the propensity score is shown in Table I in the online-only Data Supplement). These 6 variables were selected a priori to account for expected differences at the time a particular treatment strategy was selected in patient anatomy, physiology, and hemodynamic stability. To stabilize the weights, inverted propensity scores were truncated at the 1st and 99th percentiles and were normalized. Normalization consisted of dividing each individual propensity score by the mean propensity score of its respective treatment assignment. The standardized mean difference was used to quantify the relative imbalance in a covariate between the 2 treatment groups. A standardized mean difference >0.25 was considered a clinically significant imbalance. All adjusted models included the main effect of treatment and were weighted by stabilized propensity score to achieve balance between treatment groups.
To compare the effect of treatment (PDA stent versus BT shunt) on the dichotomous outcomes (use of diuretics at discharge and procedural complication), logistic regression was used, and odds ratios with 95% confidence intervals (CIs) are presented with BT shunt as the reference group. For the continuous outcomes (ICU LOS, hospital LOS, pulmonary artery symmetry index, and Nakata index), residual errors were gauged for normality via histograms and quantile-quantile plots. Failing to meet this assumption, continuous outcomes were log-transformed and reassessed for differences between interventions. Model-based mean estimates were backtransformed via exponentiation for interpretation purposes. Results are presented as means with associated 95% CIs.
Time-dependent outcomes (death, unplanned reintervention to treat cyanosis, and other reinterventions) were analyzed with survival analysis. Because most of the events occurred early in the follow-up period, the hazard was not proportional with time, and parametric survival models accounting for early failure were used. Parametric probability estimates for time-dependent outcomes were obtained with PROC HAZARD (available for download with the SAS system at https://www.lerner.ccf.org/qhs/software/hazard/). The HAZARD procedure uses maximum likelihood to resolve risk distribution of time to event in up to 3 phases of risk (early decreasing or peaking hazard, constant hazard, and late increasing hazard). Smoothed survival curves were generated with the HAZPRED procedure in SAS. Death and unplanned reintervention to treat cyanosis were also combined as a primary composite outcome. Effect of treatment on the hazard of the event of interest was quantified with the use of hazard ratios with associated 95% CIs. Because death was considered a competing event for reintervention, competing-risk analysis was performed to model the probability over time for 2 mutually exclusive end points after initial intervention, death and reintervention, with the remaining patients being alive without reintervention. Separate models were constructed for unplanned reintervention to treat cyanosis and other reinterventions. To confirm the validity of this modeling approach, time-dependent outcomes were also analyzed with Cox proportional hazard models with very similar results ( Table II in 
RESULTS
The cohort consisted of 106 patients treated with PDA stents and 251 patients treated with BT shunts. Differences in baseline demographic, anatomic, and clinical characteristics between treatment strategies are summarized in Table 1 . There were significant differences in the distribution of treatment strategy across centers, as well as a number of patient-level factors. A higher proportion of patients with pulmonary atresia with intact ventricular septum and isolated pulmonary stenosis were selected for PDA stent placement compared with other anatomic diagnosis categories. Similarly, a higher proportion of patients with an expected 2-ventricle circulation and with antegrade pulmonary blood flow at the time of initial palliation were selected for PDA stent placement. Despite this, a higher proportion of patients receiving prostaglandin infusion at the time of initial palliation were treated with a PDA stent. Patients in both groups not on prostaglandin at the time of initial palliation had either a ductus arteriosus that remained patent without need for prostaglandin or a closed ductus with antegrade pulmonary blood flow but unacceptable cyanosis. Thus, the entire cohort was considered to have ductal-dependent pulmonary blood flow. Finally, a higher proportion of patients who had an intervention before the initial palliation (the majority of which were interventions on the right ventricular outflow tract) were treated with PDA stent placement. There were no significant differences in other baseline demographic, anatomic, and clinical characteristics between the 2 groups. Of the patients palliated with a PDA stent, drug-eluting coronary stents were used in 13 patients and bare metal coronary stents in the remainder.
Unadjusted Comparisons
Comparisons of observed (unadjusted) differences in outcomes between groups are summarized in Table 2 . The primary composite outcome (death or unplanned The PDA stent group was older and had a longer time interval between the initial palliation and the definitive surgical procedure. This definitive operation was less commonly a superior cavopulmonary connection in the PDA stent group. There were no significant differences in the need for pulmonary arterioplasty at the time of the definitive surgical repair, nor were there differences in the rates of subsequent interventions on the pulmonary arteries after definitive surgical repair.
Types of Reinterventions
A description of the types of reinterventions performed, for both the unplanned reinterventions to treat cyanosis and the other reinterventions (either planned reinterventions or unplanned reinterventions to treat issues other than cyanosis), is summarized in Table 3 . Among both groups, the unplanned reinterventions to treat cyanosis most commonly involved balloon or stent angioplasty of the PDA stent or BT shunt or surgical revision. Other reinterventions occurred almost exclusively among the PDA stent group and most commonly included redilation of the stent by balloon angioplasty or, in the case of patients with antegrade pulmonary blood flow, repeat pulmonary valvuloplasty.
Propensity Score
The propensity score achieved balance among the treatment groups because the standardized mean differences after weighting were <25% for all variables used in the propensity score except anatomic diagnosis, which was nearly balanced with a standardized mean difference of 0.31. In addition, the average stabilized inverse probability of treatment weighting score was close to 1 (mean, 1.0; SD, 0.73), indicating stability in our weighting. Additional information on the propensity score can be found in Table III in the online-only Data Supplement.
Propensity Score-Adjusted Comparisons
Models assessing propensity score-adjusted differences between treatment groups in primary and secondary outcomes are summarized in Tables 4 through  6 . Adjusted differences in time-dependent primary outcomes are shown in the survival models in Table 4 . After propensity score adjustment, there was no significant difference in the hazard of the primary end point (hazard ratio, 0.8; 95% CI, 0.52-1.23; P=0. 31) or in either of the individual components of the composite end point. However, the significant difference in the hazard for other reinterventions persisted, favoring the BT shunt group (hazard ratio, 29.8; 95% CI, 9.8-91.1; P<0.001). The comparison of survivor experiences between groups for the primary composite outcome of death or unplanned reintervention to treat cyanosis is depicted in Figure 1 . A competing- ORIGINAL RESEARCH ARTICLE risk analysis of death and unplanned reintervention to treat cyanosis stratified by treatment group is displayed in Figure 2 and that for death and other reinterventions is shown in Figure 3 .
Adjusted differences in dichotomous outcomes are summarized in models shown in Table 5 . The adjusted risks of procedural complications (odds ratio, 0.4; 95% CI, 0.2-0.77; P=0.006) and being prescribed a diuretic at hospital discharge (odds ratio, 0.4; 95% CI, 0.25-0.64; P<0.001) were significantly lower in the PDA stent group.
Adjusted differences in continuous outcomes are summarized in models shown in Table 6 . The adjusted ICU LOS and hospital LOS were shorter in the PDA stent group (adjusted mean ICU LOS, 5.3 versus 9.1 days, P<0.001; hospital LOS, 13.5 versus 16.5 days, P=0.06), although the difference in hospital LOS did not attain statistical significance. Similarly, the pulmonary arteries were larger (as measured by the Nakata index) and more symmetrical in the PDA stent group after propensity score adjustment. The differences in pulmonary artery size and symmetry between the 2 treatment groups are displayed graphically in Figures 4 and 5 .
As a sensitivity analysis to assess whether the use of varying inclusion time periods for the 2 comparison groups introduced bias, all adjusted comparisons were repeated with the exclusion of patients receiving PDA stents before January 2, 2012. These results are largely unchanged and presented in Tables IV through VI in the online-only Data Supplement.
DISCUSSION
We report comparisons of a variety of clinically meaningful outcomes in infants with ductal-dependent pulmonary blood flow who were initially palliated with either a PDA stent or a BT shunt. After adjustment for patient factors, we found that there was no difference between treatment strategies in the hazard of our primary outcome, a composite of death or unplanned reintervention to treat cyanosis. However, those treated with a PDA stent had a lower risk of procedural complications, shorter ICU LOS, less use of diuretics, and larger and more symmetrical pulmonary arteries before their subsequent surgical repair or palliation. Notably, other reinterventions (both planned and unplanned to treat concerns other than cyanosis) occurred more commonly in the PDA stent group. This is by far the largest reported cohort of infants treated with PDA stent and the first from a multicenter collaborative. The overall size of the cohort and the variability in practice patterns across centers allowed comparison of the 2 treatment strategies adjusted with propensity score methods to offset the potential bias related to confounding by indication.
In the absence of a prospective study in which patients are randomly assigned to treatment strategy, we believe that this is the best possible method to compare these 2 treatment strategies in a relatively balanced fashion. We chose a priori a composite of death or unplanned reintervention to treat cyanosis as the primary outcome, with the notion that cyanosis requiring reintervention is a potential harbinger of a life-threatening event such as acute thrombotic shunt or stent occlusion. The observed risk of this composite outcome was 17% in the PDA stent group and 29.5% in the BT shunt group, a difference that was not statistically different after propensity score adjustment. It is important to interpret this finding in the context that the results of the PDA stent group are derived from a time period that covers the entire PDA stent placement experience at all centers, and thus, any "learning curve" is included in these results. Examining the individual components of this composite outcome shows that the observed risk of death was 6.6% in the PDA stent group and 10.4% in the BT shunt group, again a difference that was not statistically significant. It is important to note that this measure incorporates all-cause mortality, not only those deaths resulting from BT shunt or PDA stent dysfunction. These mortality risks are comparable to what has been previously reported and underscore the fact that patients with shunt-or ductal stent-dependent pulmonary blood flow remain a vulnerable population. In a large multicenter report from the Society of Thoracic Surgeons Congenital Heart Surgery Database, a cohort of neonates who underwent BT shunt placement without concomitant procedures experienced in-hospital mortality at a rate of 7.2% with a 13.1% rate of serious morbidity. 2 Although the at-risk period for patients in that cohort was shorter than what is included in the present study, both reports suggest that shunt procedures to provide pulmonary blood flow are associated with a high risk of early postoperative mortality and morbidity, even when compared with other types of neonatal cardiac surgery. Because this Society of Thoracic Surgeons Congenital Heart Surgery cohort excluded neonates who received other procedures (besides PDA ligation), it is likely these were predominantly patients with ductal-dependent pulmonary blood flow and 
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thus quite comparable to the cohort in the present study. Of note, 2 of the main risk factors identified for mortality in that report were preoperative mechanical ventilation and underlying cardiac anatomy, factors that were included in our propensity-adjusted models. In an older study restricted to patients with tetralogy of Fallot, mortality after BT shunt was 8.3%. 27 Finally, using an audit data set from the United Kingdom to capture a large cohort of patients who had surgery for placement of an isolated BT shunt, Dorobantu et al 3 reported an overall mortality rate of 13.9% and a 17.8% risk of shunt reintervention. Similar rates of unexpected shunt reintervention have also been reported in large single-center cohorts.
1 Data on mortality and reintervention rates after PDA stent placement are much scarcer because this procedure is newer and performed less commonly. In a handful of smaller single-center studies, reported mortality rates after PDA stent have ranged from 3.6% to 31%. 5, 6, 8, 10, 12, 13, 15 We chose to separate reinterventions into those that were unplanned to treat cyanosis versus reinterventions for other purposes (either planned reinterventions or unplanned reinterventions for issues other than cyanosis), so direct comparisons with past publications are difficult. Although the rate of unplanned reinterventions to treat cyanosis was not different between the 2 groups, it is worth noting that the rate of other reinterventions was significantly higher among the PDA stent group. This results, at least in part, from the standard practice that has developed at some of the participating centers whereby elective cardiac catheterization is performed routinely at defined intervals after initial PDA stent implantation. At such procedures, balloon angioplasty of or additional stent implantation in the existing PDA stent may occur to optimize pulmonary blood flow, even though the patient may not be more cyanotic than previously. It is possible that such planned reinterventions could affect the rate at which these patients would have developed worsening cyanosis and thus needed an unplanned reintervention to treat cyanosis. This practice is driven partially by the observation that PDA stents have a tendency to develop neointimal proliferation over time, a phenomenon that may affect their patency and durability, as highlighted by Sivakumar et al. 19 In that report, patients with 2-ventricle anatomies initially palliated with a PDA stent required complete surgical repair earlier than the typical practice at that center because of in-stent stenosis and inadequate pulmonary blood flow. This may be an issue intrinsic to stent placement in ductal tissue because there was no difference in the use of antiplatelet or anticoagulation regimens between the groups in the present study that could explain the differing reintervention rates. Despite this concern, the duration from palliation to definitive surgical repair in the present study was significantly longer in the PDA stent group, suggesting that a PDA stent can be as durable as BT shunt placement, recognizing that elective PDA stent reintervention may be used in the interim. Redilation of the PDA stents was not the only type of reintervention performed, however. Other reinterventions included those needed for recurrent right ventricular outflow tract obstruction in patients who had previously had an outflow tract intervention. Although these reinterventions were not deemed to be a harbinger of potential sudden cardiac death in this analysis, these procedures represent a real cost to the patient, in both clinical and economic terms, and thus need to be acknowledged.
Other secondary outcomes, including ICU LOS and use of diuretic at hospital discharge, all favored the PDA stent group, even after adjustment for patient fac- tors. The increased risk of being discharged on diuretics in the BT shunt group suggests that these patients were perceived to have excessive pulmonary blood or residual pulmonary edema. Alternatively, this difference could reflect differences in practice patterns in the management of postoperative patients compared with postcatheterization patients. Other measures of hospital-related morbidity such as duration of mechanical ventilation and inotrope use also favored the PDA stent. These findings are not entirely unanticipated given this comparison between invasive and minimally invasive treatment strategies. There have been a few previous head-to-head comparisons of patients receiving a PDA stent and those receiving a surgical shunt, which are worth examining in more detail. In 2012, Amoozgar et al 21 compared the short-term outcomes of 18 infants with ductal-dependent pulmonary blood flow palliated with a PDA stent at 1 institution with 20 infants treated with surgical systemic-pulmonary shunts at a second institution and found no differences between the 2 groups. McMullan et al 23 found a similar rate of reintervention between 13 infants with a PDA stent and 42 with a BT shunt at a single center but a higher rate of procedural complications and branch pulmonary artery stenosis in the BT shunt group. It is worth noting that these groups differed in underlying cardiac anatomy (primarily in the proportion of patients with pulmonary atresia). Finally, Mallula et al 22 compared 13 patients with a PDA stent with 16 with a BT shunt in a single center and found a shorter duration of hospitalization in the PDA stent group with equivalency in other short-term outcomes. However, the BT shunt group was significantly smaller in weight in this center. Comparisons adjusted for the differences in patients between groups were not performed in any of these studies.
With similarity in the primary outcome, the benefit in other short-term outcomes may favor PDA stent as the preferred strategy. However, short-term outcomes should not be the only focus, particularly when mortality is relatively uncommon. Longer-term outcomes in infants with ductal-dependent pulmonary blood flow are more challenging to measure but are likely to be influenced by the overall growth of the pulmonary arteries and pulmonary vascular bed. In both single-ventricle 28, 29 and 2-ventricle 30 anatomies, better growth and size of the pulmonary arteries have been associated with improved longer-term outcomes. In The center line of the box represents the unadjusted median; edges of the box, the unadjusted 25th and 75th percentile values; whiskers, the unadjusted 1.5×interquartile range values; and circles, the outliers. The diamond represents the propensity-adjusted mean value. The P value is the difference in the adjusted model. BT indicates Blalock-Taussig; and PDA, patent ductus arteriosus.
the present study, we found that infants palliated with PDA stent had larger (as measured by Nakata index) and more symmetrical pulmonary arteries at the time of subsequent surgical repair, a difference that persisted after adjustment for patient factors. This issue has been previously explored in depth by Santoro and colleagues. [9] [10] [11] [16] [17] [18] Over a series of articles, they demonstrated a significant symmetrical increase in pulmonary artery size in a cohort of patients with a PDA stent, 10, 18 a consistent finding in both low-and normal-weight infants 9 and in infants with severely hypoplastic pulmonary arteries 17 at the time of initial palliation. Furthermore, although the overall pulmonary artery growth in a contemporary cohort of infants palliated with BT shunts was comparable, growth was more symmetrical in the PDA stent group. 16 This difference in pulmonary artery growth may reflect differences in pulmonary artery blood flow characteristics. In our PDA stent cohort, the presence of antegrade pulmonary blood flow was more common and may have enhanced pulmonary artery size, although this factor was included in the propensity score adjustment. In addition, blood flow through the PDA stent enters the pulmonary arteries centrally, with the potential for relatively symmetrical flow to each branch pulmonary artery. In the case of a BT shunt, flow typically enters the pulmonary artery bed asymmetrically, at the site of surgical shunt insertion into one of the branch pulmonary arteries, with the risk of unilateral pulmonary artery stenosis at the site of shunt insertion further exacerbating the potential for flow asymmetry.
An additional marker of long-term pulmonary artery size and function can be measured in the need for additional interventions on the pulmonary arteries (either surgical or transcatheter). There may be a number of possible mechanisms behind the development of pulmonary artery stenosis requiring later reintervention, including the presence of shunt or stent material in the pulmonary artery or constriction of ductal tissue after stent or shunt placement that results in unilateral branch pulmonary artery stenosis. This issue, as it relates to PDA stent placement, was highlighted by Vida et al 20 in a cohort of 13 patients treated with PDA stent, of whom nearly half required additional pulmonary arterioplasty at the time of complete surgical repair and 4 needed additional later pulmonary artery interventions. In the present study, although the use of pulmonary arterioplasty at subsequent surgical repair exceeded 40%, there was no difference in this rate between treatment groups. Similarly, the rate of subsequent interventions on the pulmonary arteries was not different between the PDA stent and BT shunt groups.
The risk of procedural complications was significantly higher in the BT shunt group after adjustment for patient factors. In addition, the complications observed in the BT shunt group tended to be graver, including the need for extracorporeal membrane oxygenation, cardiac arrest, stroke, and wound infection requiring repeat surgery. In contrast, the vast majority of complications related to PDA stent procedures were vascular, most commonly occlusion of the femoral artery at the site of cannulation. This is a complication unique to the PDA stent group and is readily manageable with resolution of arterial occlusion in most patients. 31 The approach to PDA stent implantation may also require alternative access strategies, including the use of the common carotid artery or axillary artery for the more vertically oriented PDA. 32, 33 A number of limitations to the present study deserve mention. Although we attempted to adjust for all potentially relevant confounding variables, the retrospective nature of the study allows the possibility of unmeasured confounders. Specifically, we are unable to account for differences in postintervention management that may have affected outcomes. The PDA stent group includes only subjects who had technically successful stent placement. We were unable to identify patients who may have had an unsuccessful attempt at PDA stent placement or were not even considered for PDA stent on the basis of noninvasive prepalliation imaging. It is certainly possible that certain ductal anatomies may not be appropriate for PDA stent implantation, although it is beyond the scope and design of this outcomes study to explore such important technical/feasibility issues in more detail. Finally, reliable measures of pulmonary artery size at birth were not available, so we are not able to comment specifically on pulmonary artery "growth" but rather on the size of the pulmonary arteries at the time of definitive surgical repair or last follow-up. It is worth noting, however, that pulmonary artery size and symmetry continued to favor the PDA stent group after adjustment for factors (expected ultimate physiology, anatomic diagnosis, and the presence of antegrade pulmonary blood flow) that might be expected to at least partially account for baseline differences in pulmonary artery size.
CONCLUSIONS
In this large multicenter comparison of a BT shunt and a PDA stent as palliation for infants with ductal-dependent pulmonary blood flow, the first of its kind, we found no difference in the adjusted hazard of death or unplanned reintervention to treat cyanosis. Other reinterventions occurred more commonly in the PDA stent group. However, in propensity score-adjusted analysis, the risk of procedural complications and diuretic use at hospital discharge were lower, ICU LOS was shorter, and pulmonary artery size was larger and more symmetrical in the PDA stent group. In sum, we believe that these findings support the use of PDA stent as a reasonable alternative palliative therapy to BT shunt in selected patients with ductal-dependent pulmonary blood flow.
SOURCES OF FUNDING
None.
DISCLOSURES
